Lorraine E. Levitt Katz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lorraine E. Levitt Katz has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Máire Abraham
3 shared publicationsPinchas Cohen
B Division of Pediatric Endocrinology, Mattel Children’s Hospital and David Geffen School of Medicine, The University of California, Los Angeles, Calif
3 shared publicationsAbbas F. Jawad
2 shared publications- Charles A. Stanley
Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publications Kathryn M. Murphy
Univ Penn Sch Med, Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Dept Pediat, Philadelphia, PA 19104 USA
2 shared publicationsLester Baker
Division of Endocrinology/Diabetes, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania (L.E.L.K., R.J.F., C.A.S., L.B.), Philadelphia, Pennsylvania 19104-4399
2 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 177, 159-166.e1
Relationship of Cardiac Structure and Function to Cardiorespiratory Fitness and Lean Body Mass in Adolescents and Young Adults with Type 2 Diabetes
- 1 October 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 177, 159-166.e1
Relationship of Cardiac Structure and Function to Cardiorespiratory Fitness and Lean Body Mass in Adolescents and Young Adults with Type 2 Diabetes
- 5 June 2015
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 84 (1) , 62-64
C-Peptide and 24-Hour Urinary C-Peptide as Markers to Help Classify Types of Childhood Diabetes
The prevalence of different types of diabetes varies widely among regions, countries and populations [1,2]. Determining the correct type of diabetes during childhood is important to decide the optimal treatment and follow-up care as well as risk factors for families. Historically, children presenting with new diabetes were presumed to have type 1 diabetes (T1DM), originally called juvenile diabetes. Improved classification of diabetes in youth has presented clinicians with diagnostic challenges when evaluating patients. The presence of obesity and acanthosis nigricans is suggestive of type 2 diabetes (T2DM). However, given the rising prevalence of obesity in children, obesity alone does not exclude other types of diabetes. The clinical presentation of children with diabetes may range from mild hyperglycemia to ketoacidosis. Atypical diabetes in African-American children presenting with severe insulin deficiency with a subsequent noninsulin-dependent course has been recognized for several decades [3,4]. Presently, apart from genetic testing, diagnostic criteria do not always distinguish children with T1DM from maturity-onset diabetes of youth (MODY) or from T2DM.
- 5 June 2015
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 84 (1) , 62-64
C-Peptide and 24-Hour Urinary C-Peptide as Markers to Help Classify Types of Childhood Diabetes
The prevalence of different types of diabetes varies widely among regions, countries and populations [1,2]. Determining the correct type of diabetes during childhood is important to decide the optimal treatment and follow-up care as well as risk factors for families. Historically, children presenting with new diabetes were presumed to have type 1 diabetes (T1DM), originally called juvenile diabetes. Improved classification of diabetes in youth has presented clinicians with diagnostic challenges when evaluating patients. The presence of obesity and acanthosis nigricans is suggestive of type 2 diabetes (T2DM). However, given the rising prevalence of obesity in children, obesity alone does not exclude other types of diabetes. The clinical presentation of children with diabetes may range from mild hyperglycemia to ketoacidosis. Atypical diabetes in African-American children presenting with severe insulin deficiency with a subsequent noninsulin-dependent course has been recognized for several decades [3,4]. Presently, apart from genetic testing, diagnostic criteria do not always distinguish children with T1DM from maturity-onset diabetes of youth (MODY) or from T2DM.
- Open Access
- 10 December 2014
- Published by Wiley in Pediatric Diabetes
- Vol. 17 (2) , 77-86
Insulin-like growth factor-I and insulin-like growth factor binding protein-1 are related to cardiovascular disease biomarkers in obese adolescents
Context Insulin‐like growth factor (IGF)‐I and IGF binding protein (IGFBP)‐1 have been linked to cardiovascular disease (CVD) risk and pathophysiology in adults, but there are limited data in youth. Objective The aim of the study was to examine the relationship between IGF and IGFBP‐1 with traditional and non‐traditional CVD risk factors including inflammatory markers and body composition in an obese pediatric cohort. Design A cross‐sectional study. Setting The study was carried out at a university children's hospital. Subjects Sixty‐one obese non‐diabetic adolescents. Outcomes Fasting IGF‐I, IGFBP‐1, lipoprotein profiles, high‐sensitivity C‐reactive protein (hsCRP), and total adiponectin as well as insulin sensitivity measures, blood pressure (BP), and anthropometrics. Results IGFBP‐1 was negatively associated with insulin sensitivity measures, body mass index (BMI), and diastolic BP in males. IGF‐I was negatively associated with hsCRP (r = –0.479, p < 0.0005), and IGFBP‐1 was positively associated with adiponectin (r = 0.545, p < 0.0005). The IGF‐I/CRP and IGFBP‐1/adiponectin associations remained significant when controlling for both BMI and insulin sensitivity index (SI). Both IGF‐I and IGFBP‐1 were negatively associated with waist circumference (r = –0.327 and r = –0.275, respectively) and sagittal abdominal diameter (r = –0.333 and r = –0.371, respectively), while IGFBP‐1 was negatively associated with fat mass (r = –0.347, p = 0.01) as well as neck circumference and fat‐free mass in males. Controlling for BMI z‐score and SI, IGFBP‐1 remained negatively associated with diastolic blood pressure (r = 0.706, p = 0.001 and neck circumference (r = –0.548, p = 0.15) in males. Conclusions IGF‐I and IGFBP‐1 associate with CVD risk markers and may add to clinical assessments of cardiometabolic dysfunction in youth.
- 10 December 2014
- Published by Wiley in Pediatric Diabetes
- Vol. 17 (2) , 77-86
Open AccessInsulin-like growth factor-I and insulin-like growth factor binding protein-1 are related to cardiovascular disease biomarkers in obese adolescents
Context Insulin‐like growth factor (IGF)‐I and IGF binding protein (IGFBP)‐1 have been linked to cardiovascular disease (CVD) risk and pathophysiology in adults, but there are limited data in youth. Objective The aim of the study was to examine the relationship between IGF and IGFBP‐1 with traditional and non‐traditional CVD risk factors including inflammatory markers and body composition in an obese pediatric cohort. Design A cross‐sectional study. Setting The study was carried out at a university children's hospital. Subjects Sixty‐one obese non‐diabetic adolescents. Outcomes Fasting IGF‐I, IGFBP‐1, lipoprotein profiles, high‐sensitivity C‐reactive protein (hsCRP), and total adiponectin as well as insulin sensitivity measures, blood pressure (BP), and anthropometrics. Results IGFBP‐1 was negatively associated with insulin sensitivity measures, body mass index (BMI), and diastolic BP in males. IGF‐I was negatively associated with hsCRP (r = –0.479, p < 0.0005), and IGFBP‐1 was positively associated with adiponectin (r = 0.545, p < 0.0005). The IGF‐I/CRP and IGFBP‐1/adiponectin associations remained significant when controlling for both BMI and insulin sensitivity index (SI). Both IGF‐I and IGFBP‐1 were negatively associated with waist circumference (r = –0.327 and r = –0.275, respectively) and sagittal abdominal diameter (r = –0.333 and r = –0.371, respectively), while IGFBP‐1 was negatively associated with fat mass (r = –0.347, p = 0.01) as well as neck circumference and fat‐free mass in males. Controlling for BMI z‐score and SI, IGFBP‐1 remained negatively associated with diastolic blood pressure (r = 0.706, p = 0.001 and neck circumference (r = –0.548, p = 0.15) in males. Conclusions IGF‐I and IGFBP‐1 associate with CVD risk markers and may add to clinical assessments of cardiometabolic dysfunction in youth.
- 11 March 2013
- Published by Wiley in Journal of Diabetes
- Vol. 5 (4) , 456-461
Population-based survey of the prevalence of type 1 and type 2 diabetes in school children in Philadelphia (费城学龄儿童1型与2型糖尿病患病率基于人口的调查)
- 11 March 2013
- Published by Wiley in Journal of Diabetes
- Vol. 5 (4) , 456-461
Population-based survey of the prevalence of type 1 and type 2 diabetes in school children in Philadelphia (费城学龄儿童1型与2型糖尿病患病率基于人口的调查)
- 1 January 2011
- Published by Elsevier in The Journal of Pediatrics
- Vol. 158 (1) , 106-111
Glycemic Control in Youth with Type 2 Diabetes Declines as Early as Two Years after Diagnosis
- 1 January 2011
- Published by Elsevier in The Journal of Pediatrics
- Vol. 158 (1) , 106-111
Glycemic Control in Youth with Type 2 Diabetes Declines as Early as Two Years after Diagnosis
- 1 April 2007
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 8 (2) , 53-59
Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis
Children with new onset diabetes (n = 175) were evaluated over 12-months. Patients were presumptively diagnosed with type 2 diabetes mellitus (T2DM) (n = 26) based on obesity, a relative with T2DM, the ability to wean from insulin, and absence of glutamic acid decarboxylase-65 (GAD-65) antibodies. We hypothesized that markers of insulinization at diagnosis, including fasting C-peptide and insulin-like growth factor-binding protein (IGFBP)-1, in addition to initial CO(2) levels and urine ketones, would help in distinguishing type 1 diabetes mellitus (T1DM) from T2DM. Children with T1DM (84 male, 65 female) had a mean age of 8.7 +/- 4.3 yr and a racial background of 78% white, 19% black, and 3% other. In contrast, children with T2DM (13 female, 13 male) had a mean age of 14.2 +/- 3.1 yr with a racial background of 58% black, 27% white, and 15% other. Fasting C-peptide level was 0.38 +/- 0.37 ng/mL in T1DM vs. 2.66 +/- 2.14 ng/mL in T2DM; a C-peptide of 0.85 ng/mL had 83% sensitivity in distinguishing T1DM from T2DM. Fasting IGFBP-1 level was 38.1 +/- 39.1 ng/mL (T1DM) vs. 3.6 +/- 4.5 ng/mL (T2DM); a value of 3.6 ng/dL could distinguish the two types of diabetes with 93% sensitivity. Urinary ketones were found in 79% of children with T1DM compared with 56% of those with T2DM, and the magnitude was associated with type of diabetes. Initial CO(2) level for T1DM was 17.9 +/- 6.9 mmol/L vs. 22.7 +/- 5.7 mmol/L for T2DM; a value of 21.5 mmol/L could distinguish the two types of diabetes with 83% sensitivity. In addition to obesity, family history of T2DM, and absence of GAD-65 antibodies, children with new-onset T2DM may be distinguished from those with T1DM by a combination of biochemical parameters (C-peptide, IGFBP-1, CO(2), and urine ketones).
- 1 April 2007
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 8 (2) , 53-59
Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis
Children with new onset diabetes (n = 175) were evaluated over 12-months. Patients were presumptively diagnosed with type 2 diabetes mellitus (T2DM) (n = 26) based on obesity, a relative with T2DM, the ability to wean from insulin, and absence of glutamic acid decarboxylase-65 (GAD-65) antibodies. We hypothesized that markers of insulinization at diagnosis, including fasting C-peptide and insulin-like growth factor-binding protein (IGFBP)-1, in addition to initial CO(2) levels and urine ketones, would help in distinguishing type 1 diabetes mellitus (T1DM) from T2DM. Children with T1DM (84 male, 65 female) had a mean age of 8.7 +/- 4.3 yr and a racial background of 78% white, 19% black, and 3% other. In contrast, children with T2DM (13 female, 13 male) had a mean age of 14.2 +/- 3.1 yr with a racial background of 58% black, 27% white, and 15% other. Fasting C-peptide level was 0.38 +/- 0.37 ng/mL in T1DM vs. 2.66 +/- 2.14 ng/mL in T2DM; a C-peptide of 0.85 ng/mL had 83% sensitivity in distinguishing T1DM from T2DM. Fasting IGFBP-1 level was 38.1 +/- 39.1 ng/mL (T1DM) vs. 3.6 +/- 4.5 ng/mL (T2DM); a value of 3.6 ng/dL could distinguish the two types of diabetes with 93% sensitivity. Urinary ketones were found in 79% of children with T1DM compared with 56% of those with T2DM, and the magnitude was associated with type of diabetes. Initial CO(2) level for T1DM was 17.9 +/- 6.9 mmol/L vs. 22.7 +/- 5.7 mmol/L for T2DM; a value of 21.5 mmol/L could distinguish the two types of diabetes with 83% sensitivity. In addition to obesity, family history of T2DM, and absence of GAD-65 antibodies, children with new-onset T2DM may be distinguished from those with T1DM by a combination of biochemical parameters (C-peptide, IGFBP-1, CO(2), and urine ketones).
- 31 December 2006
- Published by Elsevier in The Journal of Pediatrics
- Vol. 149 (6) , 798-802.e1
Leptin levels decline steadily during prolonged fasting in lean children
- 31 December 2006
- Published by Elsevier in The Journal of Pediatrics
- Vol. 149 (6) , 798-802.e1
Leptin levels decline steadily during prolonged fasting in lean children
- Open Access
- 1 July 2005
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 63 (5) , 220-227
Pharmacodynamic Considerations with Recombinant Human Insulin-Like Growth Factor-I in Children
Aim: To report effects of weight-based recombinant human insulin-like growth factor-I (rhIGF-I) on IGF axis parameters in children with hyperinsulinism. Methods: Open label trial with subcutaneous rhIGF-I (40 µg/kg/dose). Patients studied were children (1 month to 11 years) with diffuse hyperinsulinism (n = 7). Serial serum IGF and insulin-like growth factor binding protein (IGFBP) concentrations were measured by RIA and analyzed by linear Pearson regression. Results: Following the initial rhIGF-I dose, total insulin-like growth factor-I (IGF-I) rose by 56% at 30 min (p < 0.01) and 85% at 120 min (p < 0.02). Serum IGF-II, IGFBP-2, and IGFBP-3 levels did not change. Peak serum IGF-I levels within 12 h of the initial rhIGF-I dose were 167–700 mg/ml. The variable peak IGF-I response is attributable in part to IGFBP-3 differences across this pediatric age range. Models of rhIGF-I dosing based upon body surface area (BSA) or initial IGFBP-3 resulted in predictable peak serum IGF-I levels (r = 0.78; p < 0.03). Recalculating rhIGF-I dosing based upon the BSA · IGFBP-3 product correlated closely with peak IGF-I level (r = 0.85; p < 0.007). Conclusions: Weight-based IGF-I dosing in this cohort resulted in variable IGF-I levels. Considering BSA and serum IGFBP-3 concentration in children is appropriate for subcutaneous IGF-I administration. A combination of these values may yield predictable individualization of rhIGF-I dosing.
- 1 July 2005
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 63 (5) , 220-227
Open AccessPharmacodynamic Considerations with Recombinant Human Insulin-Like Growth Factor-I in Children
Aim: To report effects of weight-based recombinant human insulin-like growth factor-I (rhIGF-I) on IGF axis parameters in children with hyperinsulinism. Methods: Open label trial with subcutaneous rhIGF-I (40 µg/kg/dose). Patients studied were children (1 month to 11 years) with diffuse hyperinsulinism (n = 7). Serial serum IGF and insulin-like growth factor binding protein (IGFBP) concentrations were measured by RIA and analyzed by linear Pearson regression. Results: Following the initial rhIGF-I dose, total insulin-like growth factor-I (IGF-I) rose by 56% at 30 min (p < 0.01) and 85% at 120 min (p < 0.02). Serum IGF-II, IGFBP-2, and IGFBP-3 levels did not change. Peak serum IGF-I levels within 12 h of the initial rhIGF-I dose were 167–700 mg/ml. The variable peak IGF-I response is attributable in part to IGFBP-3 differences across this pediatric age range. Models of rhIGF-I dosing based upon body surface area (BSA) or initial IGFBP-3 resulted in predictable peak serum IGF-I levels (r = 0.78; p < 0.03). Recalculating rhIGF-I dosing based upon the BSA · IGFBP-3 product correlated closely with peak IGF-I level (r = 0.85; p < 0.007). Conclusions: Weight-based IGF-I dosing in this cohort resulted in variable IGF-I levels. Considering BSA and serum IGFBP-3 concentration in children is appropriate for subcutaneous IGF-I administration. A combination of these values may yield predictable individualization of rhIGF-I dosing.
- 1 June 2005
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 6 (2) , 84-89
Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children
To estimate the frequency of neuropsychiatric disease (NPD) in an urban pediatric type 2 diabetes mellitus (T2DM) population, to compare demographic characteristics of affected patients with those unaffected with NPD, and to determine the frequency of psychotropic medication treatment. Retrospective chart review of patients with T2DM at the Children's Hospital of Philadelphia. Of 237 patients with T2DM, 46 (19.4%) were found to have NPD at the presentation of diabetes. Diagnoses by report included depression, attention-deficit hyperactivity disorder (ADHD), neurodevelopmental disorders, schizophrenia, and bipolar disorder. Those affected were 63% females and 37% males, with a mean age of 14.6 yr and body mass index (BMI) of 34.3 kg/m(2) at diagnosis of T2DM. Patients were 79% African American, 13% Caucasian, 4.3% Hispanic, and 4.3% Asian. There were no statistically significant differences in demographic characteristics or BMI between those affected and unaffected with NPD. Twenty-nine patients (63%) were on psychotropic medication and were prescribed 58 medications, most commonly mood stabilizers (n = 20) and atypical antipsychotics (n = 17). Our data reveal a high frequency of NPD among pediatric patients with T2DM at presentation to a tertiary care, urban medical center. Many affected patients are receiving psychotropic medication. These data have implications for screening regimens for pediatric populations at high risk for T2DM and for therapeutic interventions, including lifestyle measures.
- 1 June 2005
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 6 (2) , 84-89
Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children
To estimate the frequency of neuropsychiatric disease (NPD) in an urban pediatric type 2 diabetes mellitus (T2DM) population, to compare demographic characteristics of affected patients with those unaffected with NPD, and to determine the frequency of psychotropic medication treatment. Retrospective chart review of patients with T2DM at the Children's Hospital of Philadelphia. Of 237 patients with T2DM, 46 (19.4%) were found to have NPD at the presentation of diabetes. Diagnoses by report included depression, attention-deficit hyperactivity disorder (ADHD), neurodevelopmental disorders, schizophrenia, and bipolar disorder. Those affected were 63% females and 37% males, with a mean age of 14.6 yr and body mass index (BMI) of 34.3 kg/m(2) at diagnosis of T2DM. Patients were 79% African American, 13% Caucasian, 4.3% Hispanic, and 4.3% Asian. There were no statistically significant differences in demographic characteristics or BMI between those affected and unaffected with NPD. Twenty-nine patients (63%) were on psychotropic medication and were prescribed 58 medications, most commonly mood stabilizers (n = 20) and atypical antipsychotics (n = 17). Our data reveal a high frequency of NPD among pediatric patients with T2DM at presentation to a tertiary care, urban medical center. Many affected patients are receiving psychotropic medication. These data have implications for screening regimens for pediatric populations at high risk for T2DM and for therapeutic interventions, including lifestyle measures.
- 1 September 1999
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 84 (9) , 3117-3124
Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective β-Cell Sulfonylurea Receptor1
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in infants under 1 yr of age. HI is most often due to defective glucose-insulin coupling by the β-cell sulfonylurea receptor (SUR1) or glutamate dehydrogenase. HI-induced hypoglycemia carries significant morbidity, and current therapies are suboptimal. Insulin-like growth factor I (IGF-I) decreases insulin secretion in vitro and in healthy adults in vivo. We postulated that recombinant human IGF-I (rhIGF-I) could benefit children with HI and hypoglycemia by decreasing insulin levels and improving fasting tolerance. We enrolled nine subjects in an open label trial of rhIGF-I: eight children, ages 1 month to 11 yr, with HI due to identified mutations of SUR1 (n = 5) or clinically unresponsive to diazoxide, which acts via the SUR (n = 3), and one adult, age 32 yr, with HI due to defective glutamate dehydrogenase-1. All had suboptimal glycemic control and served as their own controls. Subjects underwent 24-h glucose monitoring under their home regimens, followed by a supervised fasting study. The controlled fast was terminated when the subject became hypoglycemic (blood glucose, vs. 6.3 ± 2.2 μIU/mL; P < 0.04) and lowered the mean serum C peptide level by 43% (2.1 ± 0.7 vs. 1.2 ± 0.6 ng/mL; P < 0.04). rhIGF-I suppression of insulin and C peptide persisted throughout the fast. The duration of fasting did not change significantly with rhIGF-I treatment. We have directly demonstrated that rhIGF-I inhibits insulin oversecretion in children with HI due to defective SUR1. Our data suggest that IGF inhibition of insulin secretion does not require an intact SUR. rhIGF-I is unlikely to be effective monotherapy for HI, but may provide synergy to inhibit insulin secretion when combined with agents acting via IGF-independent mechanisms.
- 1 September 1999
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 84 (9) , 3117-3124
Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective β-Cell Sulfonylurea Receptor1
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in infants under 1 yr of age. HI is most often due to defective glucose-insulin coupling by the β-cell sulfonylurea receptor (SUR1) or glutamate dehydrogenase. HI-induced hypoglycemia carries significant morbidity, and current therapies are suboptimal. Insulin-like growth factor I (IGF-I) decreases insulin secretion in vitro and in healthy adults in vivo. We postulated that recombinant human IGF-I (rhIGF-I) could benefit children with HI and hypoglycemia by decreasing insulin levels and improving fasting tolerance. We enrolled nine subjects in an open label trial of rhIGF-I: eight children, ages 1 month to 11 yr, with HI due to identified mutations of SUR1 (n = 5) or clinically unresponsive to diazoxide, which acts via the SUR (n = 3), and one adult, age 32 yr, with HI due to defective glutamate dehydrogenase-1. All had suboptimal glycemic control and served as their own controls. Subjects underwent 24-h glucose monitoring under their home regimens, followed by a supervised fasting study. The controlled fast was terminated when the subject became hypoglycemic (blood glucose, vs. 6.3 ± 2.2 μIU/mL; P < 0.04) and lowered the mean serum C peptide level by 43% (2.1 ± 0.7 vs. 1.2 ± 0.6 ng/mL; P < 0.04). rhIGF-I suppression of insulin and C peptide persisted throughout the fast. The duration of fasting did not change significantly with rhIGF-I treatment. We have directly demonstrated that rhIGF-I inhibits insulin oversecretion in children with HI due to defective SUR1. Our data suggest that IGF inhibition of insulin secretion does not require an intact SUR. rhIGF-I is unlikely to be effective monotherapy for HI, but may provide synergy to inhibit insulin secretion when combined with agents acting via IGF-independent mechanisms.